Journal of the National Comprehensive Cancer Network

Papers
(The TQCC of Journal of the National Comprehensive Cancer Network is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology892
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology737
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology691
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021647
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology626
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology515
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology514
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology481
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology391
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology332
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021306
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology304
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology293
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology285
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022232
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021205
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021198
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology193
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021190
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology190
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023188
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology179
NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021177
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022158
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology157
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022148
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023143
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology140
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology136
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology128
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology121
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021118
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022104
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021100
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology99
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.202198
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.202273
NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.202272
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.202272
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology69
NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.202266
NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.202353
NCCN Guidelines® Insights: Palliative Care, Version 2.202152
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.202452
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.202350
Impact of Telemedicine on Patient Satisfaction and Perceptions of Care Quality in Radiation Oncology49
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.202247
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology46
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology45
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.202244
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.202242
Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review41
Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma40
NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.202338
Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer37
Survivorship, Version 1.202136
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology36
Incident Cancer Detection During the COVID-19 Pandemic35
NCCN Guidelines® Insights: Cervical Cancer, Version 1.202435
Diagnostic and Therapeutic Delays in Patients With Hepatocellular Carcinoma35
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma32
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience32
A New Surveillance Algorithm After Resection of Colorectal Liver Metastases Based on Changes in Recurrence Risk and RAS Mutation Status32
Role of Postoperative Radiotherapy in Nonmetastatic Head and Neck Adenoid Cystic Carcinoma31
Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes30
Local Recurrence and Disease-Free Survival After Transanal Total Mesorectal Excision: Results From the International TaTME Registry30
NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.202130
Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor30
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.202229
The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer29
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors28
Adolescents and Young Adults Living With an Uncertain or Poor Cancer Prognosis: The “New” Lost Tribe27
Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer25
Association Between Chronologic Age and Geriatric Assessment–Identified Impairments: Findings From the CARE Registry24
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic24
Defining and Managing High-Risk Multiple Myeloma: Current Concepts24
Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study24
Outcomes and Predictors of 28-Day Mortality in Patients With Hematologic Malignancies and Septic Shock Defined by Sepsis-3 Criteria24
Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer23
Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer23
Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib23
Non–Small Cell Lung Cancer: Recommendations for Biomarker Testing and Treatment22
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms22
Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma21
Barriers to Optimal End-of-Life Care for Adolescents and Young Adults With Cancer: Bereaved Caregiver Perspectives21
NCCN Guidelines® Insights: Survivorship, Version 1.202321
Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer21
Cachexia and Dietetic Interventions in Patients With Esophagogastric Cancer: A Multicenter Cohort Study21
Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature21
NCCN Guidelines® Insights: Distress Management, Version 2.202320
Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score–Matched Study20
PTCH1-GLI1 Fusion–Positive Ovarian Tumor: Report of a Unique Case With Response to Tyrosine Kinase Inhibitor Pazopanib20
Non–Small Cell Lung Cancer, Version 4.202420
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study20
Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma19
Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology19
Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II–III Breast Cancer: A Multicenter Value Analysis19
Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database18
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology18
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology18
Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study18
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial18
General and Health-Related Internet Use Among Cancer Survivors in the United States: A 2013–2018 Cross-Sectional Analysis17
Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance17
Pediatric Hodgkin Lymphoma, Version 3.202117
Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response17
Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice16
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine16
Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer16
NCCN Guidelines® Insights: Survivorship, Version 1.202216
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology16
Prevalence of Insomnia in an Oncology Patient Population: An Irish Tertiary Referral Center Experience16
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.202316
Experience, Perceptions, and Recommendations Concerning COVID-19–Related Clinical Research Adjustments16
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology15
Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor–Related Esophagitis15
Diagnosis and Management of Rectal Cancer in Patients Younger Than 50 Years: Rising Global Incidence and Unique Challenges15
Proton Pump Inhibitors and Survival in Patients With Colorectal Cancer Receiving Fluoropyrimidine-Based Chemotherapy15
The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook15
Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond15
Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy15
Inherited Mutations in Chinese Men With Prostate Cancer15
Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance15
Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology14
Blastic Plasmacytoid Dendritic Cell Neoplasm14
Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology14
Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study14
Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer14
Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma14
Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults14
Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer14
Association of Polypharmacy and Potentially Inappropriate Medications With Physical Functional Impairments in Older Adults With Cancer14
Patterns and Trends of Cancer Screening in Canada: Results From a Contemporary National Survey13
How Have Multigene Panels Changed the Clinical Practice of Genetic Counseling and Testing13
Current Surveillance After Treatment is Not Sufficient for Patients With Rectal Cancer With Negative Baseline CEA13
Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival13
Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC13
Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective13
Immune-Related Adverse Events Among COVID-19–Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade13
Impact of Facility Surgical Volume on Survival in Patients With Cancer12
Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer12
The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?12
Race- and Age-Related Disparities in Cervical Cancer Mortality12
Prevalence of Anemia and Compliance With NCCN Guidelines for Evaluation and Treatment of Anemia in Patients With Gynecologic Cancer12
Smoking Cessation, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology12
Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial12
Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells12
Optimal Neoadjuvant Strategies for Locally Advanced Rectal Cancer by Risk Assessment and Tumor Location12
Impact of Axillary Dissection Among Patients With Sentinel Node–Positive Breast Cancer Undergoing Mastectomy12
NCCN Distress Thermometer Problem List Update11
Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study11
Risk of Cardiovascular Diseases Among Older Breast Cancer Survivors in the United States: A Matched Cohort Study11
Social Determinants of Health and Racial Disparities in Cardiac Events in Breast Cancer11
NCCN Guidelines® Insights: Kidney Cancer, Version 2.202411
Associations of Skeletal Muscle With Symptom Burden and Clinical Outcomes in Hospitalized Patients With Advanced Cancer11
Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III Trial11
A Survey of the National Comprehensive Cancer Network on Approaches Toward Addressing Patients’ Transportation Insecurity11
Integration of Pediatric Hodgkin Lymphoma Treatment and Late Effects Guidelines: Seeing the Forest Beyond the Trees11
Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease11
Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors11
Optimize Local Therapy for Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer to Enhance Survival11
Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia11
Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report10
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer10
Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation10
Challenges in the Histopathologic Diagnosis of Histiocytic Neoplasms10
Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers10
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer10
Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes10
Telemedicine Adoption in an NCI-Designated Cancer Center During the COVID-19 Pandemic: A Report on Patient Experience of Care9
Update on Guidelines for the Prevention of Cancer-Associated Thrombosis9
Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma9
Participation of Patients With Limited English Proficiency in Gynecologic Oncology Clinical Trials9
Validating a Patient-Reported Outcomes–Derived Algorithm for Classifying Symptom Complexity Levels Among Patients With Cancer9
Methylene Blue for the Treatment of Intractable Pain From Oral Mucositis Related to Cancer Treatment: An Uncontrolled Cohort9
Economic Analysis of Exclusionary EGFR Test Versus Up-Front NGS for Lung Adenocarcinoma in High EGFR Mutation Prevalence Areas9
Improving Health Equity and Reducing Disparities in Pediatric and Adolescent/Young Adult Oncology: In Support of Clinical Practice Guidelines9
Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology9
Patient, Caregiver, and Oncologist Experiences With and Perceptions of Racial Bias and Discrimination in Cancer Care Delivery9
Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal8
Paid Sick Leave Among Working Cancer Survivors and Its Associations With Use of Preventive Services in the United States8
Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis8
Prostate Cancer, Version 3.20248
Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients8
Primary Palliative Care Improves Uptake of Advance Care Planning Among Patients With Advanced Cancers8
Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative8
Association of Social Support With Overall Survival and Healthcare Utilization in Patients With Aggressive Hematologic Malignancies8
Underperformance of Contemporary Phase III Oncology Trials and Strategies for Improvement8
Hidden Disparities: How Language Influences Patients’ Access to Cancer Care8
Mobile Technology-Based (mLearning) Intervention to Enhance Breast Cancer Clinicians' Communication About Sexual Health: A Pilot Trial8
Quality of Life Is Associated With Survival in Patients With Gastric Cancer: Results From the Randomized CRITICS Trial8
Compound Kushen Injection Reduces Severe Toxicity and Symptom Burden Associated With Curative Radiotherapy in Patients With Lung Cancer8
Frailty in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Receiving Curative-Intent Therapy: A Population-Based Study8
Impact of Geography on Care Delivery and Survival for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis8
Expanding the Use of Nephron-Sparing Surgery for Wilms Tumor8
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors8
Surgery After Response to Chemotherapy for Locally Advanced Pancreatic Ductal Adenocarcinoma: A Guide for Management7
The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids7
Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic Malignancy7
Breast Cancer Diagnostics, Therapy, and Outcomes in Sub-Saharan Africa: A Population-Based Registry Study7
Mental Health and Chemical Dependency Services at US Cancer Centers7
Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations7
Sex- and Age-Related Differences in the Distribution of Metastases in Patients With Upper Urinary Tract Urothelial Carcinoma7
Impact of the Extent of Lymph Node Dissection on Precise Staging and Survival in Clinical I–II Pure-Solid Lung Cancer Undergoing Lobectomy7
Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment7
Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options7
Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer7
Patients With cT1N0M0 Oral Squamous Cell Carcinoma Benefit From Elective Neck Dissection: A SEER-Based Study7
Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology7
NCCN Guidelines® Updates: Kidney Cancer7
Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines7
A Prospective Cohort Study of Stability in Preferred Place of Death Among Patients With Stage IV Cancer in Singapore7
Comorbidities, Rather Than Older Age, Are Strongly Associated With Higher Utilization of Healthcare in Colorectal Cancer Survivors7
Updates in the Treatment of Metastatic Colorectal Cancer6
Evaluating if an Advance Care Planning Intervention Promotes Do-Not-Resuscitate Orders by Facilitating Accurate Prognostic Awareness6
New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer6
Cancer Treatment During COVID-19: Resilience of Individuals With Advanced Non–Small Cell Lung Cancer Versus Community Controls6
Financial Toxicity and Its Association With Prostate and Colon Cancer Screening6
Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors6
Gastrostomy Tube for Nutrition and Malignant Bowel Obstruction in Patients With Cancer6
Relationship Between Longitudinal Coping Strategies and Outcomes in Patients With Acute Myeloid Leukemia6
Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes6
Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period6
HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers6
Healthcare Cost Trajectories in the Last 2 Years of Life Among Patients With a Solid Metastatic Cancer: A Prospective Cohort Study6
Longitudinal Analysis of Mental Disorder Burden Among Elderly Patients With Gastrointestinal Malignancies6
Incident Cancer Detection During Multiple Waves of COVID-19: The Tsunami After the Earthquake6
First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort6
SOURCE: Prediction Models for Overall Survival in Patients With Metastatic and Potentially Curable Esophageal and Gastric Cancer6
Four-Year Disease-Free Remission in a Patient With POLE Mutation–Associated Colorectal Cancer Treated Using Anti–PD-1 Therapy6
Trajectories of Suffering in the Last Year of Life Among Patients With a Solid Metastatic Cancer6
Telehealth Delivery of Tobacco Cessation Treatment in Cancer Care: An Ongoing Innovation Accelerated by the COVID-19 Pandemic6
Metastatic Spiradenocarcinoma Managed With PD-1 Inhibition6
Elderly Black Non-Hispanic Patients With Head and Neck Squamous Cell Cancer Have the Worst Survival Outcomes6
Representation of Sexual and Gender Minority People in Patient Nondiscrimination Policies of Cancer Centers in the United States6
Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S02216
The Microbiome Colorectal Cancer Puzzle: Initiator, Propagator, and Avenue for Treatment and Research6
Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers6
Larotrectinib in a Patient With Advanced Pleomorphic Liposarcoma of the Uterus6
Do Editorialists With Industry-Related Conflicts of Interest Write Unduly Favorable Editorials for Cancer Drugs in Top Journals?6
Understanding Causes of Inferior Outcomes in Adolescents and Young Adults With Cancer6
Bladder Cancer, Version 3.20246
Sustainability of Tobacco Treatment Programs in the Cancer Center Cessation Initiative6
Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II–III Colorectal Cancer: A Cluster-Wide Cohort Study6
Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale6
Medicare/Medicaid Insurance, Rurality, and Black Race Associated With Provision of Hepatocellular Carcinoma Treatment and Survival6
Effect of Yoga and Mediational Influence of Fatigue on Walking, Physical Activity, and Quality of Life Among Cancer Survivors5
Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk5
Risk of Cancer-Specific Death for Patients Diagnosed With Neuroendocrine Tumors: A Population-Based Analysis5
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology5
0.062872886657715